Profile data is unavailable for this security.
About the company
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
- Revenue in USD (TTM)315.49m
- Net income in USD-746.89m
- Incorporated1999
- Employees912.00
- LocationInsmed Inc700 Us Highway 202/206BRIDGEWATER 08807United StatesUSA
- Phone+1 (908) 977-9900
- Websitehttps://insmed.com/
Mergers & acquisitions
Acquired company | INSM:NSQ since announced | Transaction value |
---|---|---|
Adrestia Therapeutics Ltd | 167.23% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viking Therapeutics Inc | 0.00 | -93.72m | 6.87bn | 28.00 | -- | 7.35 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
Intra-Cellular Therapies Inc | 513.93m | -110.87m | 7.10bn | 610.00 | -- | 10.93 | -- | 13.81 | -1.15 | -1.15 | 5.34 | 6.15 | 0.6996 | 1.67 | 4.83 | 842,508.20 | -15.09 | -38.27 | -17.67 | -42.77 | 92.82 | -- | -21.57 | -128.42 | 5.00 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
Legend Biotech Corp (ADR) | 342.80m | -465.95m | 7.29bn | 1.80k | -- | 6.27 | -- | 21.28 | -2.60 | -2.60 | 1.90 | 6.39 | 0.2297 | 9.52 | 203.86 | 190,443.30 | -31.22 | -37.71 | -37.33 | -47.19 | 52.35 | -- | -135.92 | -286.51 | 5.57 | -24.44 | 0.2233 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
Cerevel Therapeutics Holdings Inc | 0.00 | -460.47m | 7.42bn | 355.00 | -- | 13.13 | -- | -- | -2.72 | -2.72 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -44.76 | -- | -48.20 | -- | -- | -- | -- | -- | -- | -- | 0.3745 | -- | -- | -- | -23.14 | -- | -- | -- |
Bellring Brands Inc | 1.84bn | 191.50m | 7.59bn | 420.00 | 40.45 | -- | 32.08 | 4.12 | 1.44 | 1.44 | 13.84 | -1.90 | 2.40 | 5.40 | 8.71 | 4,389,286.00 | 24.91 | 18.89 | 31.72 | -- | 32.74 | 32.44 | 10.39 | 10.10 | 1.84 | 5.07 | 1.42 | 0.00 | 21.53 | 15.03 | 101.09 | 13.80 | -18.48 | -- |
Vaxcyte Inc | 0.00 | -436.82m | 7.65bn | 254.00 | -- | 3.85 | -- | -- | -4.22 | -4.22 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -28.19 | -34.22 | -29.52 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
Roivant Sciences Ltd | 124.80m | 4.35bn | 7.65bn | 845.00 | 2.04 | 1.40 | 1.80 | 61.33 | 5.07 | 5.07 | 0.1571 | 7.40 | 0.026 | 0.8187 | 2.97 | 147,686.40 | 88.04 | -- | 103.92 | -- | 87.53 | -- | 3,390.53 | -- | 25.10 | -- | 0.0642 | -- | 103.65 | -- | 487.06 | -- | -- | -- |
Repligen Corp | 607.45m | 14.84m | 8.33bn | 1.78k | 590.64 | 4.22 | 98.63 | 13.71 | 0.2524 | 0.2524 | 10.74 | 35.29 | 0.2255 | 1.43 | 4.87 | 340,689.80 | 0.551 | 4.38 | 0.6179 | 5.03 | 47.73 | 55.43 | 2.44 | 15.91 | 5.24 | -- | 0.2284 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
Exact Sciences Corp | 2.53bn | -240.23m | 8.39bn | 6.50k | -- | 2.67 | -- | 3.31 | -1.32 | -1.32 | 13.93 | 17.04 | 0.3998 | 5.28 | 11.96 | 389,975.40 | -3.79 | -9.71 | -4.13 | -10.60 | 73.67 | 74.10 | -9.48 | -28.21 | 1.45 | -- | 0.4323 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
Elanco Animal Health Inc | 4.37bn | -1.30bn | 8.74bn | 9.30k | -- | 1.44 | -- | 2.00 | -2.64 | -2.64 | 8.84 | 12.26 | 0.2931 | 1.21 | 4.28 | 469,354.80 | -8.74 | -3.27 | -9.65 | -3.65 | 55.28 | 54.28 | -29.83 | -11.53 | 1.96 | 0.853 | 0.4877 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
KBR Inc | 7.07bn | -258.00m | 8.82bn | 34.00k | -- | 6.28 | -- | 1.25 | -1.91 | -1.91 | 52.67 | 10.46 | 1.25 | -- | 5.56 | 207,970.60 | -4.45 | 0.4725 | -6.46 | 0.6678 | 13.86 | 12.18 | -3.58 | 0.4122 | -- | 1.17 | 0.5678 | 340.00 | 5.97 | 7.20 | -240.21 | -- | 36.31 | 11.03 |
Insmed Inc | 315.49m | -746.89m | 8.98bn | 912.00 | -- | -- | -- | 28.45 | -5.23 | -5.23 | 2.20 | -3.13 | 0.2357 | 0.8971 | 9.32 | 345,936.40 | -55.80 | -40.96 | -72.23 | -46.88 | 78.07 | 77.99 | -236.74 | -212.92 | 1.61 | -16.08 | 1.64 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
Catalent Inc | 4.14bn | -1.18bn | 9.73bn | 17.80k | -- | 2.68 | -- | 2.35 | -6.48 | -6.48 | 22.69 | 20.06 | 0.3993 | 4.36 | 2.87 | 232,303.40 | -11.36 | 2.88 | -12.91 | 3.26 | 18.96 | 31.03 | -28.44 | 6.35 | 1.74 | -0.4346 | 0.5797 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
Charles River Lbrtrs ntrntl Inc | 4.11bn | 438.82m | 10.74bn | 20.00k | 24.46 | 2.95 | 13.88 | 2.61 | 8.52 | 8.52 | 79.74 | 70.67 | 0.5187 | 8.38 | 5.22 | 205,579.80 | 5.69 | 6.46 | 6.53 | 7.62 | 36.45 | 36.99 | 10.97 | 11.58 | 1.37 | 4.80 | 0.4183 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 14.11m | 9.50% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 10.54m | 7.10% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 10.14m | 6.83% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 8.04m | 5.41% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 5.91m | 3.98% |
Deep Track Capital LPas of 31 Mar 2024 | 4.78m | 3.22% |
Palo Alto Investors LPas of 31 Mar 2024 | 4.42m | 2.98% |
William Blair Investment Management LLCas of 31 Mar 2024 | 4.23m | 2.85% |
Macquarie Investment Management Business Trustas of 31 Mar 2024 | 3.90m | 2.63% |
T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 3.45m | 2.32% |